为一项I期临床试验开发贝叶斯自适应设计:一种新型HIV治疗药物的案例研究
本文以评估新型肽融合抑制剂C34-PEG4-Chol安全性、药代动力学特征及抗逆转录病毒疗效的I期研究为例,介绍了在癌症以外领域建立贝叶斯自适应设计的流程。研究比较了基于持续重评估法的贝叶斯自适应设计与标准规则化设计,最终用更高效的贝叶斯自适应设计替代了原提议的规则化设计。
要点
- I期研究设计常因证据有限而具有挑战性,自适应设计在癌症以外领域应用较少。
- 研究比较了基于持续重评估法的贝叶斯自适应设计与标准规则化设计。
- 原提议的规则化设计被更高效的贝叶斯自适应设计替代。
核心结论
- 原提议的规则化设计已被更高效的贝叶斯自适应设计替代。
- 建模的结局、设计细节和评价标准具有试验特异性,但其选择原则具有通用性。
- 本案例研究展示了在新情境中建立设计所需的步骤。
研究设计与样本
- 一项评估C34-PEG4-Chol安全性、药代动力学特征及抗逆转录病毒疗效的I期研究,由医学研究理事会(Medical Research Council)资助。
- 在研究准备阶段,比较了基于持续重评估法的贝叶斯自适应设计与更标准的规则化设计,目的是选择能从研究中最大化科学信息的设计。
- 设计和评价设计选项的过程耗时,需要试验方案开发团队所有成员的积极参与。
主要发现
- 原提议的规则化设计被更高效的贝叶斯自适应设计替代。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The design of phase I studies is often challenging, because of limited evidence to inform study protocols. Adaptive designs are now well established in cancer but much less so in other clinical areas. A phase I study to assess the safety, pharmacokinetic profile and antiretroviral efficacy of C34-PEG4 -Chol, a novel peptide fusion inhibitor for the treatment of HIV infection, has been set up with Medical Research Council funding. During the study workup, Bayesian adaptive designs based on the continual reassessment method were compared with a more standard rule-based design, with the aim of choosing a design that would maximise the scientific information gained from the study. The process of specifying and evaluating the design options was time consuming and required the active involvement of all members of the trial's protocol development team. However, the effort was worthwhile as the originally proposed rule-based design has been replaced by a more efficient Bayesian adaptive design. While the outcome to be modelled, design details and evaluation criteria are trial specific, the principles behind their selection are general. This case study illustrates the steps required to establish a design in a novel context. Copyright © 2016 John Wiley & Sons, Ltd.
引用
- Mason AJ, Gonzalez-Maffe J, Quinn K, et al. Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatment. Stat Med. 2016. PMID: 27891651. doi:10.1002/sim.7169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。